Burning Rock Biotech Ltd
Research Burning Rock Biotech Ltd (BNR) on Bullrun: market cap USD 136.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBNR
- ExchangeNASDAQ
- CountryChina
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 136.09M
- Financial periodQ2 2026
- RevenueCNY 134.77M
- Net income-CNY 18.41M
- Gross margin72.6%
Valuation Snapshot
latest market cap is USD 136.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 539.57M | -CNY 55.35M | -CNY 33.69M | 74.7% | -5.1 | CNY 478.39M | CNY 43.12M | CNY 535.26M |
| FY2024 | CNY 515.82M | -CNY 346.63M | -CNY 98.24M | 70.3% | -33.7 | CNY 519.85M | CNY 52.32M | CNY 580.83M |
| FY2023 | CNY 537.44M | -CNY 653.69M | -CNY 265.17M | 67.6% | -63.8 | CNY 615.10M | CNY 12.32M | CNY 768.41M |
| FY2022 | CNY 563.24M | -CNY 971.23M | -CNY 527.28M | 67.5% | -93.5 | CNY 905.45M | CNY 50.79M | CNY 1.16B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 136.09M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 211.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 72.64M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 95.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 237.88M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.00B | n/a | n/a | n/a |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Burning Rock Biotech Ltd's market cap?
Burning Rock Biotech Ltd's market capitalization is USD 136.09M.
What does Burning Rock Biotech Ltd do?
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.